Trial Profile
Dapagliflozin to Prevent Atrial Fibrillation Recurrence After Transcatheter Pulmonary Venous Isolation.
Status:
Not yet recruiting
Phase of Trial:
Phase 0
Latest Information Update: 06 Dec 2023
Price :
$35
*
At a glance
- Drugs Dapagliflozin (Primary)
- Indications Atrial fibrillation
- Focus Therapeutic Use
- 26 Jul 2021 Planned initiation date changed from 1 Apr 2021 to 1 Sep 2021.
- 24 Mar 2021 New trial record